多中心Salomé研究纳入469例卵巢性索间质肿瘤患者:手术与化疗的影响——TMRG与GINECO协作组研究
该回顾性研究纳入法国13个中心2011年至2015年7月接受初始手术的469例成人恶性卵巢性索间质肿瘤患者,中位随访6.4年。结果显示一线治疗中年龄小于70岁、FIGO分期和完整手术与更长无进展生存期相关,化疗对早期疾病无进展生存期无影响,复发时完整手术可延长无进展生存期而围手术期化疗无影响。结论认为化疗在一线或复发场景均未影响生存,仅手术及其质量在任何治疗线中显示无进展生存期获益。
要点
- 一线治疗中年龄小于70岁、FIGO分期和完整手术与更长无进展生存期相关。
- 化疗对早期(FIGO I-II)疾病的无进展生存期无影响。
- 复发时完整手术可统计学显著延长无进展生存期,围手术期化疗无影响。
核心结论
- 化疗在性索间质肿瘤的一线或复发场景中均未影响生存。
- 仅手术及其质量在任何治疗线中显示对卵巢性索间质肿瘤无进展生存期的获益。
研究设计与样本
- 回顾性分析法国罕见恶性妇科肿瘤网络13个中心的数据。
- 纳入2011年至2015年7月期间接受初始手术的469例成人恶性性索间质肿瘤患者。
主要发现
- 75%诊断为成人型颗粒细胞瘤,23%为其他亚型。
- 中位随访6.4年,154例(33%)发生首次复发,82例(17%)发生两次复发,49例(10%)发生三次复发。
- 初始诊断时14.7%的患者接受辅助化疗;首次、第二次和第三次复发时围手术期化疗使用率分别为58.5%、28.2%和23.8%。
- 一线治疗中年龄小于70岁、FIGO分期和完整手术与更长无进展生存期相关。
- 一线治疗中BEP方案与其他化疗方案的无进展生存期相似(HR 0.88 [0.43; 1.81])。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Identifying prognostic factors and evaluating the impact of adjuvant chemotherapy in patients with sex cord stromal tumors (SCST) is crucial. In this study, we aimed to address these challenges. METHODS: We conducted a retrospective analysis of data from 13 centers of the French Rare malignant gynecological tumors (TMRG) network. We enrolled 469 adult patients with malignant SCST who received upfront surgery since 2011 to July 2015. RESULTS: 75% were diagnosed with adult Granulosa cell tumors, and 23% had another subtype. With a median follow-up of 6.4 years, 154 patients (33%) developed a first recurrence, 82 (17%) two recurrences, and 49 (10%) three recurrences. Adjuvant chemotherapy was administered in 14.7% of patients at initial diagnosis. In relapse, perioperative chemotherapy was administered in 58.5%, 28.2%, and 23.8% of patients, respectively, in the first, second, and third relapse. In the first-line therapy, age under 70 years, FIGO stage, and complete surgery were associated with longer progression-free survival (PFS). Chemotherapy had no impact on PFS in early-stage disease (FIGO I-II). The PFS was similar using BEP or other chemotherapy regimens (HR 0.88 [0.43; 1.81]) in the first-line therapy. In case of recurrence, PFS was statistically prolonged by complete surgery, but perioperative chemotherapy use did not impact PFS. CONCLUSION: Chemotherapy use did not impact survival in the first-line or relapse setting in SCST. Only surgery and its quality demonstrated benefit for PFS in ovarian SCST in any lines of treatment.
引用
- Hanvic B, Lecuru F, Vanacker H, et al. Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study. Gynecol Oncol. 2023. PMID: 37210929. doi:10.1016/j.ygyno.2023.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。